Interim report, foreign filer
Open the filing on sec.gov
Quantum Biopharma Ltd. (QNTM)
Nasdaq: QNTM · Pharmaceutical Preparations · Toronto · filing with the SEC since 2019
The companyfiscal 2019, as filed
RevenueC$257,099
Net income-C$52.0M-129.0%
Earnings per sharen/a
Operating cash flow-C$18.2M+1.4%
CashC$7.9M-62.5%
Debtn/a
Shareholders’ equityC$48.2M-5.5%
Shares, diluted108,558+19.5%
Return on equity-107.9%
The recordfrom its filings
Filings in 202633
Newest filingNov 12 · 6-K
Annual reportMar 26, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents grantedn/a
Filer categoryNon-accelerated filer<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in CAD. Nothing here is a forecast.
News
Interim report, foreign filer
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Large holder update, amended
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.